Tourmaline Bio CEO Sandeep Kulkarni and Talaris interim CEO Mary Kay Fenton
Tourmaline Bio reverse merges into Talaris and raises funds to target thyroid eye disease and pharma rivals
Talaris Therapeutics will hand over its spot on the Nasdaq to Tourmaline Bio in a reverse merger to fund trials of an ex-Pfizer drug it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
